GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (NAS:LRMR) » Definitions » Shares Outstanding (Diluted Average)

Larimar Therapeutics (Larimar Therapeutics) Shares Outstanding (Diluted Average) : 53.55 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Larimar Therapeutics's average diluted shares outstanding for the quarter that ended in Mar. 2024 was 53.55 Mil.


Larimar Therapeutics Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Larimar Therapeutics's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Shares Outstanding (Diluted Average) Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
9.21 11.88 17.16 25.76 43.90

Larimar Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.90 43.90 43.90 43.91 53.55

Larimar Therapeutics Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Larimar Therapeutics  (NAS:LRMR) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Larimar Therapeutics Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Larimar Therapeutics (Larimar Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Executives
Gopi Shankar officer: Chief Development Officer C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA 19004
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Russell Clayton officer: Chief Medical Officer 2600 KELLY RD, WARRINGTON PA 18976
Carole Ben-maimon director, officer: President and CEO C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Michael Celano officer: Chief Financial Officer 220 EAST FIRST STREET, BETHLEHEM PA 18015
Joseph Truitt director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Thomas Edward Hamilton director 211 STUYVESANT AVE, RYE NY 10580
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Jonathan S Leff director C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Hif, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Chondrial Therapeutics Holdings, Llc 10 percent owner 150 MONUMENT ROAD, SUITE 207, BALA CYNWYD PA 19004
Deerfield Mgmt Iv, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Healthcare Innovations Fund, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iii, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017